WordNet

of or relating to the pituitary gland; "pituitary hormone"
the master gland of the endocrine system; located at the base of the brain (同)pituitary_gland, pituitary body, hypophysis
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
the secretion of an endocrine gland that is transmitted by the blood to the tissue on which it has a specific effect (同)endocrine, internal_secretion

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells.

Ma Q1, Xia X1, Tao Q1, Lu K1, Shen J1, Xu Q1, Hu X1, Tang Y1, Block NL1, Webster KA1, Schally AV1, Wang J1, Yu H2.
Arteriosclerosis, thrombosis, and vascular biology.Arterioscler Thromb Vasc Biol.2016 Apr;36(4):663-72. doi: 10.1161/ATVBAHA.116.307126. Epub 2016 Feb 11.
OBJECTIVE: The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia.APPROACH AND RESUL
PMID 26868211

Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Romero MJ1, Lucas R2, Dou H3, Sridhar S3, Czikora I3, Mosieri EM3, Rick FG4, Block NL5, Sridhar S6, Fulton D7, Weintraub NL8, Bagi Z8, Schally AV9.
Proceedings of the National Academy of Sciences of the United States of America.Proc Natl Acad Sci U S A.2016 Feb 16;113(7):1895-900. doi: 10.1073/pnas.1525520113. Epub 2016 Feb 1.
Dyslipidemia associated with triglyceride-rich lipoproteins (TRLs) represents an important residual risk factor for cardiovascular and chronic kidney disease in patients with type 1 diabetes (T1D). Levels of growth hormone (GH) are elevated in T1D, which aggravates both hyperglycemia and dyslipidemi
PMID 26831066

Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance.

Galimov A1,2, Hartung A1, Trepp R3, Mader A4, Flück M5,6, Linke A7, Blüher M8, Christ E3, Krützfeldt J9,10,11.
Journal of molecular medicine (Berlin, Germany).J Mol Med (Berl).2015 Dec;93(12):1369-79. doi: 10.1007/s00109-015-1322-y. Epub 2015 Jul 23.
Replacement of growth hormone (GH) in patients suffering from GH deficiency (GHD) offers clinical benefits on body composition, exercise capacity, and skeletal integrity. However, GH replacement therapy (GHRT) is also associated with insulin resistance, but the mechanisms are incompletely understood
PMID 26199111

リンク元	「下垂体ホルモン調節ホルモン受容体」「下垂体ホルモン調節ホルモンレセプター」
関連記事	「pituitary」